| 廖兴辉,许春伟,王文娴.非小细胞肺癌患者RAS基因突变临床特征和预后分析[J].肿瘤学杂志,2018,24(7):676-681. |
| 非小细胞肺癌患者RAS基因突变临床特征和预后分析 |
| non small cell lung cancer；nidogen-1；cathepsClinical Features and Prognosis of Non-small Cell Lung Cancer with RAS Mutationsin S；risk factors |
| 投稿时间：2017-06-16 |
| DOI：10.11735/j.issn.1671-170X.2018.07.B005 |
|
 |
| 中文关键词: 非小细胞肺癌 RAS 临床特征 预后 |
| 英文关键词:non-small-cell lung cancer RAS clinical features prognosis |
| 基金项目:浙江省科技厅公益类科研计划 (2015C33194)；嘉兴市科技计划项目（2016AY23087） |
|
| 摘要点击次数: 2979 |
| 全文下载次数: 479 |
| 中文摘要: |
| 摘 要：［目的］ 探讨非小细胞肺癌RAS基因突变的临床特征和预后。［方法］ 对475例非小细胞肺癌患者进行RAS基因检测和随访。Kaplan-Meier法计算生存率，Log-rank法进行生存率检验。［结果］ 475例非小细胞肺癌中，KRAS基因突变的突变率为8.00% (38/475)，其中吸烟患者的KRAS突变频率远高于非吸烟患者(15.76% vs 4.41%，P<0.01)。 346例非小细胞肺癌中NRAS基因突变的突变率为0.29% (1/346)；315例非小细胞肺癌中HRAS基因突变的突变率为0.63% (2/315)。RAS基因复合其他基因突变15例，中位生存时间29.8个月；而单纯RAS突变26例中位生存时间16.3个月(P=0.15)。［结论］ 在NSCLC患者中，吸烟患者的KRAS基因突变频率高于非吸烟患者。RAS基因突变的非小细胞肺癌临床特征上无统计学差异；复合突变比单纯突变临床获益更多。 |
| 英文摘要: |
| Abstract：［Objective］ To investigate clinical features and prognosis of non-small cell lung cancer with RAS mutations. ［Methods］ RAS mutations were detected in 475 cases with non-small cell lung cancer，and the clinical features from 41 NSCLC patients with RAS mutations were retrospectively reviewed. Survival was calculated by Kaplan-Meier method and Log-rank test. ［Results］ KRAS gene mutation rate was 8.00%(38/475） in 475 patients with non-small cell lung cancer，the mutation rate of current-smoker was much higher than no-smoker(15.76% vs. 4.41%，P<0.01）. NRAS gene mutation rate in 346 patients with non-small cell lung cancer was 0.29%(1/346），and HRAS gene mutation rate in 315 patients with non-small cell lung cancer was 0.63%(2/315）. 15 cases of RAS mutation patients accompanied with other gene mutation，the median overall survival time was 29.8 months，the median overall survival time of the other 26 simple RAS mutation cases was 16.3 months without statistical difference(P=0.15）. ［Conclusion］ Mutation rate of KRAS gene in current-smoker NSCLC patients is higher than no-smoker，there is no other significant difference of clinical features in RAS gene mutations in non-small cell lung cancer. Patients with complex mutations benefited more from therapy than those with single RAS mutations. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |